Aavantgarde: AAVantgarde Bio Closes 61M Series A Financing

AAVantagarde Bio, a Milan, Italy-based clinical-stage, biotechnology company developing two proprietary Adeno-Associated Viral (AAV) vector platforms, raised €61M in Series A funding. The round was co-led by Atlas Venture and Forbion, with participation from Longwood Fund and founding investor Sofinnova Partners through its Sofinnova Telethon Fund. In connection with the Series A financing, Jason Rhodes [...]The post AAVantgarde Bio Closes €61M Series A Financing appeared first on FinSMEs.